0001372514-24-000014.txt : 20240214 0001372514-24-000014.hdr.sgml : 20240214 20240214155156 ACCESSION NUMBER: 0001372514-24-000014 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20240214 DATE AS OF CHANGE: 20240214 EFFECTIVENESS DATE: 20240214 FILER: COMPANY DATA: COMPANY CONFORMED NAME: KIORA PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001372514 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-505316 FILM NUMBER: 24637178 BUSINESS ADDRESS: STREET 1: 332 ENCINITAS BOULEVARD STREET 2: SUITE 102 CITY: ENCINITAS STATE: CA ZIP: 92024 BUSINESS PHONE: 781-788-8869 MAIL ADDRESS: STREET 1: 332 ENCINITAS BOULEVARD STREET 2: SUITE 102 CITY: ENCINITAS STATE: CA ZIP: 92024 FORMER COMPANY: FORMER CONFORMED NAME: EYEGATE PHARMACEUTICALS INC DATE OF NAME CHANGE: 20060811 D 1 primary_doc.xml X0708 D LIVE 0001372514 KIORA PHARMACEUTICALS INC 332 ENCINITAS BOULEVARD SUITE 102 ENCINITAS CA CALIFORNIA 92024 619-629-3073 DELAWARE EYEGATE PHARMACEUTICALS INC Corporation true Brian Strem 332 Encinitas Blvd., Suite 102 Encinitas CA CALIFORNIA 92024 Executive Officer President and Chief Executive Officer Melissa Tosca 332 Encinitas Blvd., Suite 102 Encinitas CA CALIFORNIA 92024 Executive Officer Executive VP of Finance Eric Daniels 332 Encinitas Blvd., Suite 102 Encinitas CA CALIFORNIA 92024 Executive Officer Chief Development Officer Carmine Stengone 332 Encinitas Blvd., Suite 102 Encinitas CA CALIFORNIA 92024 Director Aron Shapiro 332 Encinitas Blvd., Suite 102 Encinitas CA CALIFORNIA 92024 Director Kenneth Gayron 332 Encinitas Blvd., Suite 102 Encinitas CA CALIFORNIA 92024 Director Praveen Tyle 332 Encinitas Blvd., Suite 102 Encinitas CA CALIFORNIA 92024 Director David Hollander 332 Encinitas Blvd., Suite 102 Encinitas CA CALIFORNIA 92024 Director Erin Parsons 332 Encinitas Blvd., Suite 102 Encinitas CA CALIFORNIA 92024 Director Pharmaceuticals Decline to Disclose 06b false 2024-02-05 false true true true false 0 Maxim Group LLC 120708 None None 300 Park Avenue, 16th Floor New York NY NEW YORK 10022 All States false 15000000 15000000 0 The common stock and warrants sold for a combined purchase price of $0.5524. Amount excludes any proceeds from a cash exercise of warrants. false 13 1050000 0 Amount excludes any placement agent fees payable with respect to a cash exercise of warrants. 0 Some of the proceeds may be used for working capital and other general corporate purposes, which may include the payment of salaries and other fees to those listed in Item 3. false KIORA PHARMACEUTICALS INC /s/ Melissa Tosca Melissa Tosca EVP of Finance 2024-02-14